REG - N4 Pharma PLC - New Patent Filing

N4 PharmaAnnouncement

04/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241204:nRSD6757Oa&default-theme=true

RNS Number : 6757O  N4 Pharma PLC  04 December 2024

4 December 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

 

New Patent Filing

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
novel RNA therapeutics usings its proprietary delivery systems, is pleased to
announce it has filed a new patent for its oral anti-inflammatory Irritable
Bowel Disease ("IBD") product in early pre-clinical development.

 

The orally delivered product uses the unique capabilities of the Company's
Nuvec® delivery system to target the macrophage cells responsible for the
inflammation associated with IBD. Each Nuvec® nanoparticle contains two
separate RNA, an siRNA to inhibit the production of TNF-alpha and an mRNA to
promote the body's natural anti-inflammatory defenses. By delivering these RNA
together locally in the gut, the symptoms of IBD can be more readily treated.

 

The patent has been filed with the UK patent office.

 

Please visit the N4 Pharma Investor Hub to submit any questions and find more
information, including an additional video by Nigel Theobald, CEO:
https://investors.n4pharma.com/link/XyO8oe
(https://investors.n4pharma.com/link/XyO8oe) .

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are excited by the potential of this product as it not only addresses a
strong clinical need to replace injectable TNF-alpha inhibitors and other oral
solutions with significant side effects, it also showcases the key features of
the Nuvec® system, namely the ability to protect the payload, target delivery
to a particular cell type and load multiple RNA onto the one nanoparticle.

 

"By filing the patent, we are now able to talk in more detail to our investors
and potential collaborators about this product and will shortly provide an
update on the in-vitro work we have completed giving more detail regarding our
approach."

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                          Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director                              Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 Investor questions on this announcement                      https://investors.n4pharma.com/link/XyO8oe

                                                            (https://investors.n4pharma.com/link/XyO8oe)
 We encourage all investors to share questions

 on this announcement via our investor hub

 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

Glossary

 

RNA: Ribonucleic acid, present in all living cells

 

mRNA: messenger RNA, whose role is to carry protein information from the DNA
in a cell's nucleus to the cells cytoplasm to produce a particular protein.

 

siRNA: small interfering RNA, a short double-stranded RNA, one of whose
strands can complement and inactivate a sequence mRNA to stop protein
production.

 

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing unique nucleic acid
based products using its patented delivery systems Nuvec® and Liptide®. Its
first two products are an oral anti-inflammatory product for IBD and an siRNA
to knock down MRTF-B which reduces scarring post Glaucoma surgery. As well as
these it is looking to develop further oncology and gene therapy products.

 

Its novel delivery systems are also available to third parties for licensing
to develop their own products in oncology, gene therapy and vaccines for
upfront payments, milestone payments and ultimately royalty payments once
products reach the market.

 

It is also seeking partners or investors to take its initial products into
phase 1 clinical trials.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDTJBRTMTIMBII